Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1 2Phase 1/2 1

Status

Recruiting 4Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Non-Hodgkin 2Recurrence 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Hodgkin Disease 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 148Biopsy 117pembrolizumab 91Carboplatin 85Cisplatin 77Nivolumab 71Cyclophosphamide 69Paclitaxel 64Gemcitabine 52Radiotherapy 48Bevacizumab 44durvalumab 41Dexamethasone 37Fluorouracil 35Doxorubicin 35venetoclax 34Pemetrexed 33Capecitabine 33olaparib 32Rituximab 31Oxaliplatin 31Injections 31atezolizumab 30Etoposide 29fludarabine 28Radiation 28Prednisone 28Lenalidomide 27Docetaxel 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × polatuzumab vedotin × 30 days × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06765317 2026-06-01

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
42 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-29

MK-2140-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
594 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M.D. Anderson Cancer Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell

NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Completed
42 enrolled 10 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡